These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 15663548

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses.
    Koshikawa S, Akizawa T, Kurokawa K, Marumo F, Sakai O, Arakawa M, Morii H, Seino Y, Ogata E, Ohashi Y, Akiba T, Tsukamoto Y, Suzuki M.
    Nephron; 2002 Apr; 90(4):413-23. PubMed ID: 11961400
    [Abstract] [Full Text] [Related]

  • 3. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
    Lu KC, Tseng CF, Wu CC, Yeung LK, Chen JS, Chao TY, Janckila AJ, Yam LT, Chu P.
    Blood Purif; 2006 Apr; 24(5-6):423-30. PubMed ID: 16888370
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Apr; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.
    Tamura S, Ueki K, Mashimo K, Tsukada Y, Naitoh M, Abe Y, Kawai H, Tsuchida A, Wakamatsu R, Nojima Y.
    Clin Exp Nephrol; 2005 Sep; 9(3):238-43. PubMed ID: 16189633
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.
    Takahashi F, Furuichi T, Yorozu K, Kawata S, Kitamura H, Kubodera N, Slatopolsky E.
    Nephrol Dial Transplant; 2002 Sep; 17 Suppl 10():46-52. PubMed ID: 12386269
    [Abstract] [Full Text] [Related]

  • 9. Suppression of parathyroid hormone secretion in CAPD patients by intraperitoneal administration of Maxacalcitol.
    Murakami K, Miyachi H, Watanabe A, Kawamura N, Fujii M, Koide S, Murase M, Kushimoto H, Hasegawa M, Tomita M, Hiki Y, Sugiyama S.
    Clin Exp Nephrol; 2004 Jun; 8(2):134-8. PubMed ID: 15235930
    [Abstract] [Full Text] [Related]

  • 10. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L, Carboni C, Stipo L, Malaguti V, Ferrari F, Graziani R, Arletti S, Graziosi C.
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [Abstract] [Full Text] [Related]

  • 11. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
    Monier-Faugere MC, Geng Z, Friedler RM, Qi Q, Kubodera N, Slatopolsky E, Malluche HH.
    Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
    [Abstract] [Full Text] [Related]

  • 12. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [Abstract] [Full Text] [Related]

  • 13. Decreased blood lead levels after calcitriol treatment in hemodialysis patients with secondary hyperparathyroidism.
    Lu KC, Wu CC, Ma WY, Chen CC, Wu HC, Chu P.
    Bone; 2011 Dec; 49(6):1306-10. PubMed ID: 21985997
    [Abstract] [Full Text] [Related]

  • 14. Time course of change in calcium x phosphorus product after percutaneous ethanol injection therapy.
    Koiwa F, Hasegawa T, Kojima I, Ideura T.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii53-7. PubMed ID: 12771302
    [Abstract] [Full Text] [Related]

  • 15. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
    Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D.
    Kidney Int; 2003 Apr; 63(4):1483-90. PubMed ID: 12631365
    [Abstract] [Full Text] [Related]

  • 16. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J, Martin KJ, González EA, Acchiardo SR, Valdin JR, Soltanek C.
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
    Hayashi M, Tsuchiya Y, Itaya Y, Takenaka T, Kobayashi K, Yoshizawa M, Nakamura R, Monkawa T, Ichihara A.
    Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
    [Abstract] [Full Text] [Related]

  • 18. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study.
    Kurokawa K, Akizawa T, Suzuki M, Akiba T, Ogata E, Slatopolsky E.
    Nephrol Dial Transplant; 1996 Aug; 11 Suppl 3():121-4. PubMed ID: 8840326
    [Abstract] [Full Text] [Related]

  • 19. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
    Kiattisunthorn K, Wutyam K, Indranoi A, Vasuvattakul S.
    Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
    [Abstract] [Full Text] [Related]

  • 20. A study of maintenance therapy after intravenous maxacalcitol for secondary hyperparathyroidism.
    Adachi M, Miyoshi T, Shiraishi N, Shimada H, Sakaguchi S, Tomita K, Kitamura K.
    Clin Nephrol; 2011 Oct; 76(4):266-72. PubMed ID: 21955861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.